Tecon Biology (SHE:002100) subsidiary Tecon Pharmaceutical received a decision from the Beijing Stock Exchange terminating its initial public offering review, according to a Tuesday filing with the Shenzhen bourse.
The termination follows a "significant decline" in operating performance in 2025 and the first quarter of 2026 due to weak market conditions, challenges in the downstream livestock sector and higher VAT rates on biological products.
Tecon Biology said the subsidiary's revenue contribution is low, with no material impact on operations or finances. It will also not trigger the mandatory delisting of Tecon Pharmaceutical.
Shares of the agricultural and biotech company closed 3% lower Tuesday.